Penpulimab Plus Anlotinib Evaluated for Previously Treated Urothelial Cancers
Dr Siefker-Radtke provides her closing thoughts on her takeaways from ESMO 2022, including a study focusing on penpulimab plus anlotinib.
Exploring the Role of Disitamab Vedotin in the Treatment of Metastatic Urothelial Cancer
Disitamab vedotin is a promising antibody-drug conjugate option undergoing evaluation for patients with metastatic urothelial cancer.
SOGUG-AUREA Trial Results Impacting Next-Steps for Bladder Cancer Treatment
Dr Siefker-Radtke shares takeaways from the SOGUG-AUREA study and its influence on treatment for patients with urothelial cancer.
Unmet Needs in Management of Patients With MDS
Unmet needs in MDS treatment management are proposed by Salman Fazal, MD.
Cost-Reduction Strategies in MDS Treatment Pathway
Dr Haumschild leads a discussion regarding cost-associated burden for patients with MDS.
Burden of Treatment Failure in MDD
Major depressive disorder treatment failure can lead to subsequent costs and poor outcomes, affecting payer considerations in the treatment landscape.
Potential Consequences of Recurrent or Poorly Controlled MDD
Consequences attributed to poorly controlled and recurrent MDD are evaluated by Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP.
SOGUG-AUREA Study Overview
The SOGUG-AUREA study explored overall survival of atezolizumab plus split-dose cisplatin-gemcitabine in patients with locally advanced and metastatic urothelial cancer.
EV+P Combination Strategy Changing Bladder Cancer Treatment Landscape
Enfortumab vedotin monotherapy or its combination with pembrolizumab could significantly evolve the treatment landscape for urothelial cancer.
Oral Therapies in MDS Treatment Strategy
Drs Fazal and Zeidan illustrate the roles and challenges of implementing oral therapies in MDS treatment management.
Utilizing Care Pathways in Treatment of MDS
Clinical pathways in MDS treatment are explored by Amer Zeidan, MBBS, MHS, and Jay Weaver, PharmD, MPH.
MDD Treatment Landscape
Expert panelists discuss the lack of diversity among available treatment options for MDD.
Unmet Needs in Treatment of MDD
Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP, open a discussion surrounding payer considerations relating to the treatment of major depressive disorder (MDD).
Unmet Needs of Patients with Locally Advanced Metastatic Urothelial Cancer (mUC)
Dr Siefker-Radtke explores unmet needs in the treatment of patients with urothelial cancer and how novel immunotherapies can address some of the challenges with traditional chemotherapy.
Payer Considerations for Selecting Optimal MDS Treatment Approach
Key considerations for appropriate MDS treatment selection are discussed by expert panelists.
Hypomethylating Agents Impacting MDS Treatment Landscape
Salman Fazal, MD, shares opinions regarding the role of hypomethylating agents (HMAs) in treatment for patients with MDS.
Enfortumab Vedotin (EV) Monotherapy and Pembrolizumab (P) Combination Treatments in Urothelial Cancer
Arlene Siefker-Radtke, MD, opens a discussion recapping the ESMO 2022 conference surrounding advanced and metastatic urothelial cancer.
Emphasizing Biomarker-Driven Treatment and Individualized Care Strategies for Patients With NSCLC
Dr Millie Das, MD discusses updates from the 2022 World Conference on Lung Cancer regarding non-small cell lung cancer (NSCLC).
Optimizing Treatment Pathways for Patients with ESCC and GI Cancer
Syma Iqbal, MD, shares final insights into the ESCC and GI cancer treatment landscape, emphasizing the utilization of key diagnostic tools and innovative treatment strategies.
Supportive Care Needs for Patients with MDS
Experts discuss the impact of supportive care in the MDS treatment landscape.
Assessing Treatment Goals for Patients with MDS
Drs Zeidan and Fazal share their opinions on setting appropriate goals for treatment of patients with MDS.
JAVELIN Lung 100 Trial Evaluating Progression-Free and Overall Survival for Patients With NSCLC
Millie Das, MD, outlines the JAVELIN Lung 100 trial and shares insights on strategies and data interpretation from the trial.
Quality of Life Impacted by Treatment of ESCC and Upper GI Cancer
Syma Iqbal, MD, discusses how ESCC and GI cancer treatment pathways may have a myriad of effects on patient quality of life.
Aligning ESCC and GI Cancer Treatment Strategies With Current Guidelines
A medical expert discusses treating patients with ESCC and GI cancers as recommended by current FDA and NCCN guidelines.
Drivers of Health Resource Management in MDS
Jay Weaver, MD, highlights MDS treatment strategies driven by optimal health resource management.
Challenges Surrounding Access to Care for Patients With MDS
Expert panelists explore challenges impacting care access for patients with MDS.
Improving Patient Access to Biosimilars
In her final thoughts, Dr Oskouei discusses how patient care may be improved by increased access to biosimilars.
HUDSON Trial Overview and Key Takeaways
The HUDSON trial is explored by Dr Das as she provides an overview of the study and offers key considerations regarding results.
Trajectory of Vitiligo Treatment Landscape
Experts provide closing pearls regarding the current and prospective treatment landscape of vitiligo.
Payer Support for Emerging Vitiligo Treatments
The panel discusses emerging treatments for vitiligo and addresses opportunities for payers to support implementation.
